MeiraGTx has entered a $400M financing agreement with Oberland Capital, including $375M in royalty funding and $25M equity, to support late‑stage AAV gene therapies for xerostomia, XLRP, and LCA4 through regulatory and commercial milestones.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
MeiraGTx Holdings has secured a financing agreement of up to $400 million with Oberland Capital Management to support the development and commercialization of its late-stage gene therapy pipeline. The transaction includes up to $375 million in non-dilutive royalty-based funding and up to $25 million in equity investment, providing capital without significant shareholder dilution while supporting planned regulatory and commercial milestones over the next several years.
Pipeline Assets
The agreement covers three investigational adeno-associated virus (AAV) gene therapies: AAV2-hAQP1 for grade 2/3 late radiation-induced xerostomia (RIX), botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa (XLRP), and AAV-AIPL1 for Leber congenital amaurosis type 4 (LCA4). Following regulatory approvals, Oberland Capital will receive low single-digit capped royalties on net sales of these products.
Scientific and Clinical Context
MeiraGTx develops genetic medicines using adeno-associated viral vectors to deliver functional genes directly to affected tissues. Its lead candidates target serious disorders with limited or no approved disease-modifying therapies.
AAV2-hAQP1 delivers the human aquaporin-1 gene to salivary glands to restore saliva production in patients who develop chronic dry mouth after radiation therapy for head and neck cancer. Bota-vec delivers a functional RPGR gene to retinal cells to treat XLRP, an inherited retinal disease that progressively causes vision loss and blindness. AAV-AIPL1 targets mutations in the AIPL1 gene, a rare inherited retinal disorder that leads to severe visual impairment early in life.
Funding Structure and Milestones
The transaction provides $135 million in initial funding, consisting of $125 million in royalty financing and a $10 million equity investment.
Additional funding will become available as development milestones are achieved. MeiraGTx may access $50 million following positive data from the Phase 2 AQUAx2 trial evaluating AAV2-hAQP1 in 2027, another $50 million upon potential regulatory approval of bota-vec in 2027, and $50 million following potential approval of AAV2-hAQP1 in 2028. The agreement also includes up to $100 million for future products or business development activities upon mutual agreement, while Oberland Capital retains the option to purchase an additional $15 million in company equity.
Royalty obligations remain capped at predetermined multiples of the invested capital, and the agreement allows MeiraGTx to repurchase the royalty note under specified conditions, preserving strategic flexibility for future partnerships or potential corporate transactions.
Strategic Implications
President and Chief Executive Officer Alexandria Forbes, Ph.D. said the financing reflects confidence in the clinical data generated for the company’s lead gene therapy programs and provides substantial non-dilutive capital as MeiraGTx prepares for potential commercial launches. She noted that structuring royalties across multiple late-stage assets enables the company to raise significant funding while maintaining flexibility for future business development opportunities.
Michael Bloom, Partner at Oberland Capital, said the investment was supported by the company’s portfolio of three gene therapies that could reach regulatory approval within the next 12 to 24 months, addressing diseases with significant unmet medical need and no approved therapeutic alternatives.
Path Forward
The financing strengthens MeiraGTx’s balance sheet as it advances multiple regulatory submissions and prepares for commercial launch activities. Near-term milestones include Phase 2 AQUAx2 data expected in 2027, potential regulatory decisions for bota-vec in 2027, and AAV2-hAQP1 in 2028. If successful, the agreement provides a flexible source of capital to support commercialization while limiting shareholder dilution and preserving long-term strategic options.
Reference
About the Writer
Chikkula Pavan Kumar (LinkedIn), PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.